Vienna BioCenter
Toggle Navigation
Apply
Contact
Research
Back
Research at Vienna BioCenter
Research Areas
Back
Biochemistry, Biophysics, Structure
Cell and Chromosome Biology
Computational Biology, Genomes and Evolution
Disease Mechanisms, Immunology, Pathogens
Gene Regulation, RNA, Epigenetics
Neurobiology
Stem Cells, Development, Regeneration
Research Groups
Key Discoveries
Back
CRISPR/Cas9
MECHANISMS OF CHROMOSOME SEGREGATION
HUMAN BRAIN ORGANOIDS
EPIGENETICS
1001 GENOMES
Recent Research Highlights
Vienna Covid-19 Detection Initiative
Research Entities
Biotech Companies
Facilities
Events
Career
Facilities
Back
Advanced Microscopy
Child Care Center
Electron Microscopy
Histopathology
Metabolomics
Next Generation Sequencing
Plant Sciences
Preclinical Phenotyping
Protein Technologies
Vienna Drosophila Resource Center
VBCF Landing Page
VBCF Staff
Projects & Grants
VBCF Jobs
VBCF Events
MyVBCF
Companies
Back
Companies at Vienna BioCenter
Biotech Companies
Back
a:head
Ablevia Biotech
ACCANIS Biotech
Aelian Biotechnology
Affiris
Akribes
Allcyte
Apeiron Biologics
Ares Genetics
Austrianni
Bird-C
CALYXHA Biotechnologies
ChanPharm
EUCODIS Bioscience
Eveliqure
Evercyte
G.ST Antivirals
Haplogen
Hookipa Pharma
JLP Health
Lexogen
Miti Biosystems
OncoOne
Origimm
PhagoMed
Phenaris
QUANTRO Therapeutics
SCARLETRED
TAmiRNA
Thermo Fisher Scientific
Valneva
X4 Pharmaceuticals
Service Companies
Back
Biolution
LabConsulting
net4biz
VBTCG CONSULTING GMBH
Business Incubators
Back
CEBINA
INiTS
Scientific Association
Back
ÖGMBT
Education
Career
Back
Open Positions
Why Work Here
Back
Campus Life
Child Care Center
Life in Vienna
About
Back
About Vienna BioCenter
VBC at a Glance
Back
Who is Here (Members)
History
Management Team
Virtual Tour
Key Discoveries
Events
Back
cryo-EM Symposium
News
(current)
Downloads
Career
Contact
Back
Media Contacts
Search
VBC
About
News
Valneva Reports Q1 Results and Updates 2020 Guidance Following Major Lyme Partnering Deal
07 May'20
Valneva reported its first quarter financial results ending March 31, 2020.
Read more
Back
